# Using Drug Levels and Drug Resistance Testing to Select Effective Anti-HIV Drug Combinations in Patients With Drug-resistant HIV

> **NCT00027339** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 53 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** lopinavir/ritonavir
- **DRUG:** indinavir sulfate
- **DRUG:** tenofovir disoproxil fumarate
- **DRUG:** ritonavir
- **DRUG:** fosamprenavir

## Key facts

- **NCT ID:** NCT00027339
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** 2005-06
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2021-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00027339

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00027339, "Using Drug Levels and Drug Resistance Testing to Select Effective Anti-HIV Drug Combinations in Patients With Drug-resistant HIV". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00027339. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*